Figure 7 — Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis

Research Paper|Volume 13, Issue 1|pp. 450–459

Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis

Back to articleFigure 7(7 of 8)

100%

Figure 7.Forest plots comparing any-grade and grade 3–4 non-hematological/any AEs. (A) Grade 3–4 fatigue; (B) any-grade fatigue; (C) grade 3–4 headache; (D) any-grade headache.